Purpose of review This review will summarize the symptoms, evaluation, and treatment of neonatal and iatrogenic withdrawal syndromes.
INTRODUCTION
Recent studies have shown an increase in neonatal abstinence syndrome (NAS) over the last decade [1 & ]. During the same time period, increased awareness of the need for adequate pain control and sedation in critically ill children resulted in more liberal use of opioids and benzodiazepines, leading to an increased incidence of iatrogenic chemical dependence. These two trends prompt the need to review the identification, management, and prevention of withdrawal syndromes in pediatrics.
The best-described withdrawal syndrome is NAS that occurs after birth, when intrauterine exposure to certain substances is abruptly discontinued. This has been documented for opioids, benzodiazepines, selective serotonin reuptake inhibitors, mood stabilizers, and nicotine [2 && ,3 && ]. A similar syndrome occurs when critically ill infants and children develop physical dependence on medications, most commonly opioids and benzodiazepines, used to achieve analgesia and sedation. Withdrawal commonly becomes an issue in critically ill, mechanically ventilated patients who often require prolonged sedation [4] . Inadequate attention to withdrawal can lead to life-threatening complications, patient discomfort, and prolonged hospital stays. The following article serves to review the current literature on prevention, recognition, and management of withdrawal syndromes in pediatrics.
RISK FACTORS
Both human and drug characteristics impact the severity of withdrawal as measured by the length of hospital stay and the need for pharmacologic therapy.
]. Although Jansson et al. [8] found increased symptoms and need for greater pharmacologic therapy in males, multiple other studies found each sex to be equally affected [9, 10] . Wachman et al. [11] believe that they may have identified a single nucleotide polymorphism that is associated with more severe NAS. Maternal factors predictive of worse neonatal withdrawal symptoms include polysubstance use (opioids and benzodiazepines in particular) [6, 12, 13 & ] and perinatal methadone use, whereas maternal use of buprenorphine (BPH) predicts less severe symptoms [8, 14] . Some controversy surrounds whether or not increased maternal methadone dosage is associated with an increased rate or severity of symptoms [13 & , 15, 16] . It does appear that maternal dose has a positive correlation with length of hospital stay [7 & ], but if the mother has not used opioids within 1 week of delivery there is a lower risk of NAS [3 && ].
Iatrogenic withdrawal
There are multiple risk factors that contribute to the development of iatrogenic withdrawal. Regardless of the medication dose, genetic variations influence individual response to opioid analgesia and development of tolerance [4] . There are also drug-related risk factors that have been identified in children, including rapid tapering or abrupt discontinuation of opioids and benzodiazepines, length of exposure/ duration of treatment, and high total cumulative dose [3 && ,4,14,17-19] . Although data on defining high dose vary, exceeding 5-7 days of therapy has consistently been identified as a risk factor. A recent clinical report published by the American Academy of Pediatrics (AAP) suggests that setting a threshold at 2 mg/kg of fentanyl exposure or 7 days' duration of therapy would predict likelihood of withdrawal to fall between 50-100% [3
Keeping these criteria in mind can aid in identifying children at greatest risk of withdrawal, developing assessment tools, and initiating weaning protocols appropriately.
SYMPTOMS
In order to assess, treat, or ideally prevent withdrawal syndromes, it is essential not only to identify risk factors, but also to recognize the symptoms.
Neonatal withdrawal
The timing and features of withdrawal symptoms in NAS depend on the substance. ]. Most of the understanding of pediatric withdrawal has been derived from research on intrauterine drug-exposed newborns and opioid-addicted adults [14] . Symptoms of opioid withdrawal are similar in newborns and children [14] ; however, unlike in neonates, most critically ill ventilated children receive both opioids and benzodiazepines. The concurrent use of these medications makes it difficult to differentiate the symptoms of one from the other. Research suggests that they have a similar withdrawal profile, perhaps with the exception of gastrointestinal symptoms observed in opioid withdrawal. Major symptoms of benzodiazepine withdrawal in children are included in Recognition and treatment of opioid withdrawal are confounded by concurrent benzodiazepine withdrawal.
Assessment of iatrogenic withdrawal remains challenging given the paucity of research beyond the neonatal period.
Evidence-based clinical guidelines are needed for optimal management of pediatric withdrawal syndromes.
symptoms have been described on the basis of single case reports and small case series that correspond to studies in adult patients [14] . A recent larger prospective study by Ista et al. [19] expanded to include all 24 symptoms of opioid and benzodiazepine withdrawal described in the literature for ICU patients. Unlike previous studies, this study suggested that gastrointestinal symptoms such as vomiting and diarrhea may also be part of benzodiazepine withdrawal [19] , making differentiation even more challenging.
ASSESSMENT
In order to optimally treat withdrawal, one must both recognize the symptoms and have an objective-validated reliable tool to measure severity.
Neonatal withdrawal
The majority of research on neonatal withdrawal has used the Finnegan Scale [26] , or the modified Finnegan Scale, as these scales were developed in 1975 [27, 28] (Table 2 ). These scales, developed on term and near-term infants, score infant behaviors associated with withdrawal [15] . The infant is evaluated every 4 h and their Finnegan Score is based on behaviors during that period. If the score is greater than or equal to 8 on any three consecutive ratings, the average of two scores is greater than or equal to 12, or the scores for two consecutive ratings are greater than or equal to 12, the infant should be started on pharmacologic therapy [29 & ]. A survey of accredited neonatology fellowships showed that only slightly more than half had a written NAS policy, and fewer than three-quarters used a published NAS scoring system [30] . Despite these statistics from accredited training programs, any healthcare organization that serves neonates should adopt a single abstinence scoring form to avoid individual variation in assessment [3 && ]. Direct instruction and education regarding the scoring sheet improves interrater reliability and decreases subjectivity [29 & ,31 && ]. Infants with known intrauterine exposure should be monitored for at least 72 h.
Iatrogenic withdrawal
Adequate pain control and sedation have caused an increased incidence of tolerance, physical dependence, and subsequent withdrawal mainly from morphine, fentanyl, and midazolam (the most commonly used agents). This is largely observed in critically ill children in the Pediatric Intensive Care Unit (PICU). Studies have suggested that opioid withdrawal occurs in as many as 57% of PICU patients [4, 14, [18] [19] [20] 32] and the incidence of benzodiazepine withdrawal ranges from 17-35% depending on the study [14, 17, 19, 33] . Although adequate pain control and sedation are considered essential, the consequences of oversedation include increased time on ventilator support, prolonged PICU stay and overall lengthened hospital course, highlighting the need for balance. Despite this, evidence-based practice guidelines for appropriate Adapted from [28] .
management of analgesia/sedation and withdrawal are lacking and assessment remains challenging. Most research in iatrogenic withdrawal syndrome relies on tools validated only in the neonate, scoring some clinical findings only observed during the neonatal period, such as the moro reflex, which disappears by 3 months of age, or high-pitched cry [14, 34, 35] . These scales have limited clinical application given issues with validity, frequency of assessments, and absence of guidelines for pain and sedation management in most PICUs [34] . In addition, during evaluation it is often difficult to differentiate the signs and symptoms of withdrawal from those of illness, inadequate pain control/sedation, or agitation from medical interventions such as mechanical ventilation [19] , potentially leading to overdiagnosis of withdrawal.
Multiple assessment tools have been used to score symptom severity in iatrogenic withdrawal syndrome, the newest and most promising being the Withdrawal Assessment Tool (WAT-1) and the Sophia Observation Withdrawal Symptoms-scale (SOS). Franck et al. [24, 35, 36 & ] developed and studied the WAT-1 during a prospective study in two University-affiliated PICUs enrolling children weaning from more than 5 days of continuous opioid and benzodiazepine infusions. It examined 19 withdrawal symptoms derived from the Opioid Benzodiazepine Withdrawal Scale (OBWS), previously the only tool with prospective validation in PICU patients, in combination with literature review and expert opinion. This study suggested that the WAT-1 was superior to the OBWS, demonstrating improved sensitivity in detecting withdrawal symptoms (87% as compared with 50%) and a specificity of 88%, when using a score of greater than or equal to 3 to define significant withdrawal [24, 35] (Table 3) . Later Franck et al.
[24] performed a similar study expanded to include 22 PICUs to support validity, reliability, and generalizability of the WAT-1 in measuring iatrogenic withdrawal. The authors confirmed their previous findings. Although WAT-1 has advantages over previous tools in that it is simpler and less time consuming to use, it is limited in that the scale lacks symptoms specific to benzodiazepine withdrawal, making it better in identifying withdrawal from opioids. Additionally, both studies were confounded by polypharmacy, with 39% of patients in the initial study receiving one to three nonopioid/nonbenzodiazepine medications [24, 35] .
Investigations by Ista et al. used the self-developed Sophia Benzodiazepine Opioid Withdrawal Checklist (SBOWC) to expand from previous studies and include all withdrawal symptoms from benzodiazepines and opioids described in the literature [19,34,36 & ]. This prospective, repeated measures study included children who received greater than or equal to 5 days of continuous IV opioid and/or benzodiazepine infusion [19, 34] and used the SBOWC as the basis for constructing the SOS to monitor iatrogenic withdrawal symptoms in PICU patients [23] . The prevalence of withdrawal syndromes in this study correlated with previous scales; however, almost 75% of the patients were infants, suggesting that the symptoms may not necessarily apply to older children [19, 34] . As the SOS included more benzodiazepine withdrawal symptoms than the WAT-1, the authors concluded that this tool was a more sensitive scale for detecting benzodiazepine withdrawal [23] . Because most PICUs utilize both opioids and benzodiazepines simultaneously in their intubated patients, the SOS may offer an advantage over the WAT-1 once cut-off scores, sensitivity, and specificity are delineated, an important factor given the different treatment.
MANAGEMENT
The management techniques used to resolve withdrawal symptoms depend in part on the substance use that led to the withdrawal and in part on the age and circumstance of the patient.
Neonatal withdrawal
The goal of the therapy is to relieve signs of withdrawal and to prevent complications such as fever, weight loss, and seizures [3 && ]. Although between 50 and 95% of all opioid-exposed infants require pharmacologic therapy [15] . It should be noted that breastfeeding is only to be encouraged among mothers whose drug use is limited to methadone or BPH. Use of illicit drugs is a contraindication for breastfeeding. Although no current research documents the efficacy of acupuncture in the treatment of NAS, one study did find active points in infants with withdrawal symptoms [39] . These active points may be sites for intervention in future studies. Wherever possible, it is important that the parents and family be encouraged to actively participate in management of NAS, to promote bonding between parent and child and to provide opportunity to observe interactions assessing for social risks and safety [29 & ]. There have been many studies evaluating single and multidrug therapies for NAS [40, 41] showed benefit over methadone for length of treatment and length of hospital stay [43] . Other benefits include a ceiling effect for respiratory depression, and less cardiovascular lability than methadone [43] . Interestingly, the serum concentration of BPH required for amelioration of symptoms in neonates is significantly less than that required for adults [43] .
With all of the above opioid replacement therapies, it is sometimes necessary to add an additional agent (Table 4) ]. The most common adjunctive therapy is phenobarbital. It has been found to be useful in controlling the hyperactive symptoms of withdrawal, but ineffective in managing the gastrointestinal symptoms [15] . A recent Cochrane Review concluded that phenobarbital was better than diazepam as an adjunct, particularly if there has been multidrug exposure [40] . There is some concern about the neurodevelopmental effects of phenobarbital on the neonate, which may be addressed in the [41] .
Clonidine has also shown utility as an adjunctive therapy. When combined with an opioid, it decreases the length of treatment [29 & ,46] and reduces morphine dosages required for neonates exposed to heroin or methadone. Studies showed an increased rate of rebound, but a shorter course of treatment overall. At this time, there are no published studies regarding the use of clonidine and BPH.
Two medications not recommended in the management of NAS are chlorpromazine and naloxone [15] . Although helpful in controlling the gastrointestinal and CNS effects of withdrawal, chlorpromazine has many side effects, including decreased seizure threshold and cerebellar dysfunction [15] . Naloxone in the drug-exposed neonate can be lifethreatening by precipitating acute withdrawal and seizure activity.
Although much of the current research in pharmacotherapy for NAS uses the compounds described above, there are novel strategies being considered such as targeting serotonergic pathways, developing immunotherapies, using vaccines and antibodies, and further investigating pharmacogenomics [47 & ]. These novel approaches may prove safer and have better outcomes than the traditional therapies for NAS.
Iatrogenic withdrawal
Recognizing the dearth of guidelines for the management of iatrogenic withdrawal, The United Kingdom Paediatric Intensive Care Society, Analgesia and Neuromuscular Blockade Working Group published multidisciplinary consensus guidelines to help establish consistency in analgesia and sedation practices for critically ill children [33] . This was followed in 2012 by a clinical report published by the AAP recommending reasonable practices based on available evidence to help predict and manage acquired opioid and benzodiazepine dependency [3 && ]. Both reports cite a lack of high-quality evidence to support recommendations, and thus there is still no optimal regimen for treatment of pediatric iatrogenic withdrawal.
Methadone is the most common agent used to treat opioid withdrawal in children given its good bioavailability and long half-life allowing for extended dosing intervals. There are a number of weaning protocols available, each with variations in dosages, weaning increments, and length of the weaning period. In a prospective, double-blind, randomized trial of patients who received fentanyl with or without benzodiazepine infusion for greater than or equal to 5 days, Bowens et al. [32] found no advantage of high-dose over low-dose methadone in successfully completing a 10-day taper regardless of total dose or length of fentanyl therapy. Unfortunately, the results were confounded by concurrent benzodiazepine withdrawal and by use of a nonvalidated assessment tool. In addition, 42% of patients enrolled in the study failed to complete the taper because of deviations from protocol. Another small study looking at a similar population found no difference in withdrawal symptoms between five and 10-day weaning protocols [36 & ]. The optimal rate of methadone tapering is not clear, with one study reducing doses 10-20% daily depending on length of wean resulting in an 87% incidence of withdrawal symptoms [14,36 & ]. Five to 10% incremental reductions are typical in adult patients [14] . Perhaps the key is not the details of the protocol, but adherence to a single protocol.
Given the prevalence of withdrawal in the PICU, a structured strategy for therapy is needed. Reasonable practices based on available evidence outlined in the AAP clinical report [3 && ] include: establishment of weaning protocols, based on likelihood of drug dependence, which are initiated when certain dosage thresholds are exceeded. Medications can be tapered rapidly over 24 to 48 h if the defined threshold has not been surpassed, as there is decreased likelihood of withdrawal in these patients; selection of a standardized rescue protocol for withdrawal symptoms that guides conversion to methadone and lorazepam [36 & ], one example outlined in Table 5 [3 && ,20] . Use of such protocols has been shown to decrease total duration of methadone therapy [20] and incidence of withdrawal symptoms [36 & ]. Interestingly, recent literature suggests that even when guidelines are in place practitioners may not consistently follow them [21 & ]; adoption of the idea that 80% of children can successfully be weaned from methadone in 5-10 days and that the duration of benzodiazepine wean should be proportional to the days of therapy; selection of one assessment tool to be used consistently in monitoring patients for signs and symptoms of withdrawal; adoption of a policy to observe young children for signs and symptoms of withdrawal for 24-48 h after discontinuation of opioid therapy; recognition that use of clonidine, chloral hydrate, or low-dose naloxone infusion [48] has not been proven to reduce withdrawal. One small case series suggests that transdermal clonidine may be useful in prevention of opioid withdrawal [49] with additional limited evidence to suggest dexmedetomidine may play a similar role [50] . However, both 
PREVENTION
It is important to remember that fetal exposure to opioids can occur when the mother is addicted to either prescription or illicit opioids, or required opioids for the management of another disease process, or is maintained on an opioid agent to facilitate well-tolerated withdrawal from addiction [31 && ]. Although abrupt cessation of drug use during pregnancy is not recommended, there are maternal behaviors that diminish the likelihood or severity of NAS. The risk of complications from illicit opioid use in pregnancy is significant, and pregnant women should be assisted in the transition to a substitute for heroin. If the mother already receives substitutive maintenance therapy, there is data to support BPH over methadone, and either is preferable to morphine [51] . Infants born to mothers on morphine maintenance tend to have quicker-onset withdrawal and worse NAS symptoms [51] . The MOTHER study, a large multicenter randomly controlled trial of mothers on opioid therapy, has contributed a great deal to our understanding of NAS [52] . Infants born to mothers on BPH maintenance therapy (BMT) or methadone maintenance therapy (MMT), had the same percentage of infants requiring treatment, but the infants born to mothers on BMT had higher birth weights [53] , required less morphine and had shorter hospital stays than their counterparts on MMT [52, 53] . Unfortunately, there was also a higher rate of drop out for mothers in the BMT group when compared with the MMT group, likely due to the decreased opioid effect of BPH [52] . Given that concurrent benzodiazepine use is associated with prolonged length of stay and complicates scoring withdrawal symptoms in NAS, mothers should be counseled to discontinue use during pregnancy [6, 12] .
CONCLUSION
Neonatal and iatrogenic withdrawal syndromes are complex problems for which simple solutions do not exist. Despite a high incidence of withdrawal in critically ill PICU patients and increased occurrence of NAS, strong evidence-based guidelines do not exist to guide therapy. A consistent approach to assessment and treatment is key, including the following components: refinement of a practical tool for identification of withdrawal symptoms that is simple, efficient, and possesses strong interrater reliability; development of a structured weaning protocol based on clinical evidence;1; and production of new pharmacologic agents targeted at the pathophysiology and symptomatology of withdrawal. A retrospective chart analysis from BC Children's Hospital in Vancouver, British Columbia, to investigate practitioner adherence to institutional methadone weaning protocol in 43 critically ill PICU patients ages 1 week to 17 years receiving 5 days or more of continuous intravenous morphine infusion. In this study, none of the patients started on the prescribed weaning protocol completed the methadone taper, suggesting that even with a protocol in place consistent clinical practice remains difficult to obtain. 22. 
